DPLM:LSEDiploma PLC Analysis
Data as of 2026-06-07 - not real-time
£7,020.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Diploma PLC is trading at £7,020, comfortably above its 20‑day SMA of 6,898.5 and 50‑day SMA of 6,726.8, while still higher than the 200‑day SMA of 5,755.4, confirming a bullish long‑term trend. The RSI of 55.9 indicates modest momentum and the MACD histogram is slightly negative with a bearish signal line, suggesting a near‑term pause as price approaches the resistance level of £7,160. Volatility is elevated at 26.3% (30‑day) but beta is low at 0.25, meaning the stock is less sensitive to market moves yet can swing sharply. Recent earnings delivered a 36% YoY EPS increase and 16.8% revenue growth, sparking a 6% rally and prompting analysts to raise the median target to £7,500. The Fear & Greed Index at 83 (“Extreme Greed”) reflects strong investor enthusiasm.
Despite the momentum, valuation remains stretched: a trailing PE of 49.8 versus an industry average of 30, a price‑to‑book of 8.96×, and a DCF‑derived fair value of only £4,493, indicating the market is pricing a substantial premium. Forward PE improves to 28, and the dividend yield of 0.9% with a 44% payout ratio appears sustainable given solid free cash flow. Debt of £501 m (debt‑to‑equity 47.5%) is manageable against a ROE of 19% and operating cash flow of £284 m. The mix of strong growth fundamentals and high valuation leads to a nuanced outlook: short‑term caution near resistance, medium‑term upside of roughly 7.6%, and a long‑term need for price convergence to fundamentals.
Despite the momentum, valuation remains stretched: a trailing PE of 49.8 versus an industry average of 30, a price‑to‑book of 8.96×, and a DCF‑derived fair value of only £4,493, indicating the market is pricing a substantial premium. Forward PE improves to 28, and the dividend yield of 0.9% with a 44% payout ratio appears sustainable given solid free cash flow. Debt of £501 m (debt‑to‑equity 47.5%) is manageable against a ROE of 19% and operating cash flow of £284 m. The mix of strong growth fundamentals and high valuation leads to a nuanced outlook: short‑term caution near resistance, medium‑term upside of roughly 7.6%, and a long‑term need for price convergence to fundamentals.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price approaching key resistance at £7,160
- Bearish MACD signal suggesting short‑term pause
- Elevated volatility but low beta limiting market‑wide swings
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Analyst median target of £7,500 implying ~7.6% upside
- Strong revenue growth (16.8%) and EPS acceleration (36% YoY)
- Improving forward PE to 28 and solid free cash flow
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Valuation gap between market price and DCF fair value
- Sustainable dividend with healthy payout ratio
- Diversified geographic footprint reducing concentration risk
Key Metrics & Analysis
Financial Health
Revenue Growth16.80%
Profit Margin11.50%
P/E Ratio49.8
ROE18.95%
ROA10.78%
Debt/Equity47.45
P/B Ratio9.0
Op. Cash Flow£283.9M
Free Cash Flow£244.3M
Industry P/E30.2
Technical Analysis
TrendBullish
RSI55.9
Support£6,600.00
Resistance£7,160.00
MA 20£6,898.50
MA 50£6,726.80
MA 200£5,755.43
MACDBearish
VolumeStable
Fear & Greed Index83.02
Valuation
Fair Value£4,492.51
Target Price£7,553.75
Upside/Downside7.60%
GradeOvervalued
TypeBlend
Dividend Yield0.90%
Risk Assessment
Beta0.25
Volatility26.27%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.